Xiaochuan 'David' Liu

The dynamic nature of the biotech industry requires operational flexibility in clinical development. One primary way biotech achieves this adaptive environment is by outsourcing at least some of its clinical development functions. In the past, they would most often turn to a full-service outsourcing (FSO) model to meet their needs. However, they are increasingly finding value in hybrid solutions that make room for services and capabilities delivered from a functional service provider (FSP) partner as well. https://lnkd.in/dmXCh2QG

4

Incomplete data hinders drug discovery. 💊🔬 Researchers unveil #QComp (QSAR-Complete), a data completion approach that enhances QSAR model predictions by leveraging correlations in experimental data across multiple endpoints. A step towards more efficient drug development! 🚀 Quick Read: https://lnkd.in/g-bs-gPX #bioinformatics #drugdevelopment #qsar #ai #neuralnetworks #drugdiscovery #sciencenews

6

You still can register for the webinar to learn on how others use single cell data to further their research.

4

15 High-Priority Hiring Roles (Director-Level) Director of Drug Discovery / Translational Research 1. A company creating livers by differentiating iPS cells (Kansai) 2. A company creating pancreases by differentiating iPS cells (Kansai) 3. A company creating hearts using iPS/organoids (Tokyo) 4. A company creating kidneys by differentiating iPS cells (Kansai) 5. A company creating cardiac sheets from iPS-derived cells (Kansai) 6. A company aiming to treat autoimmune diseases using CAR-T (Tokyo) 7. A company aiming to treat autoimmune diseases using T-reg (US) Director of CMC Process Development 8. A company creating pancreases by differentiating iPS cells (Kansai) 9. A company creating hearts using iPS/organoids (Tokyo) 10. A company creating kidneys by differentiating iPS cells (Kansai) 11. A company curing muscular dystrophy using AAV vectors for gene therapy (Kyushu) Head of QA 12. A company creating cardiac sheets from iPS-derived cells (Kansai) 13. A company creating retinas from iPS cells (Tokyo) Head of Business Development 14. A company creating organs such as pancreases and livers by differentiating iPS cells (Flexible location—ideal candidates include professionals from Takeda or Helios!) CEO 15. Multiple positions available. Regenerative medicine companies focusing on various modalities, especially iPS-based therapies. As you can see, many of the roles involve iPS-related research. If you or someone you know might be interested, please feel free to reach out directly. Referrals are greatly appreciated, and we can offer a referral fee in the range of 100,000–500,000 JPY, depending on the situation. #iPS #TranslationalResearch #Hiring #CGT

15

1 Comment

For those interested in Physiologically Based Biopharmaceutics Modeling (PBBM) please check out our recently published article from the 2023 PBBM workshop. It proposes best practices for measuring solubility, dissolution, precipitation and permeability for parameterizing PBBMs, summarizes breakout sessions, and shares PBBM case studies. https://lnkd.in/gda_HH4F

95

2 Comments

Check out our paper how we are revolutionizing data sharing using GenAI to understand informed consent documents. This work could easily be widely leveraged across the industry and with other data use agreements allowing appropriate data reuse. #TeamBiogen

14

🚀 Transforming Drug Discovery with ASPIRE10X’s RDF Knowledge Graph Platform 🚀 As part of our ongoing efforts at ASPIRE10X, our team has developed a real-time RDF Knowledge Graph platform that integrates critical data sources like DrugBank, Disease Ontology, and UniProt. This platform creates interconnected real -time RDF for knowledge graphs to provide valuable insights into drug-target interactions, disease pathways, and drug repurposing opportunities. Key Impact: 1) Accelerating Drug Discovery: Real-time data integration and visualization optimize drug design and identify therapeutic targets faster. 2) Improved Decision-Making: A unified platform to explore relationships between drugs, diseases, and molecular data, enhancing R&D efficiency. 3) Personalized Medicine: Supporting tailored treatments by analyzing molecular profiles and disease-specific data. 4) Collaboration & Efficiency: Streamlined research with dynamic, shareable knowledge graphs for teams across the industry. Platform Features: 1) Cloud-Hosted: Hosted on Azure, providing flexibility and high availability for users worldwide. 2) Scalable: Easily scalable to meet the growing demands of pharmaceutical research and data analysis. 3) Containerized: Ensuring seamless deployment, management, and updates across diverse environments. By leveraging semantic technologies and knowledge graphs, ASPIRE10X’s platform is accelerating drug discovery and reshaping how the pharmaceutical industry approaches R&D. 🔗 Explore the ASPIRE10X RDF Knowledge Graph Platform and how it's transforming drug discovery: https://lnkd.in/g9RhUpjS

7

“What’s unique about China’s RWE?” China is the 2nd largest single-country drug market in the world, with >70% market share of RWE businesses in APAC. But, how unique are China’s RWE studies? How much “local” do you need to know to design a scientifically sound RWE study? I believe there are at least five factors making China’s RWE studies really interesting: 1. The medical bill system: have you heard DIP(if not, see paper pasted below)? Simply speaking, to avoid doctors over-treating patients, the government sets a system, where a “fair” price is determined for a group of diseases. If the actual expense is (far) beyond limit, not the insurance, not the patient, but the doctor who prescribes the expensive medicine will have to pay from his own wallet. The impact on RWD/RWE? Well, should I explain more? Sometimes there is argument on Real World Evidence vs. True World Evidence in China. Is it unique?

9

“What’s unique about China’s RWE?” China is the 2nd largest single-country drug market in the world, with >70% market share of RWE businesses in APAC. But, how unique are China’s RWE studies? How much “local” do you need to know to design a scientifically sound RWE study? I believe there are at least five factors making China’s RWE studies really interesting: 2. Chinese FDA has lower risks to approve “imported” drugs and medical devices. So C-FDA encourages the use of RWE to generate evidence. You may have already heard the Hainan RWE Heaven (an island where you can bring your drugs or medical devices already approved overseas to China with RWE only), or the CARE program for patient centered Rare Disease clinical development plan, or the Pediatric RWE pilot study, etc. While other regulatory bodies are still “talk the talk”, C-FDA is “Walk the Walk”, thanks to the lower risks. Interestingly enough, experts say that FDA has a recent ruling in Florida. Is Florida the “Hainan in the USA”? Is it unique?

8

“What’s unique about China’s RWE?” China is the 2nd largest single-country drug market in the world, with >70% market share of RWE businesses in APAC. But, how unique are China’s RWE studies? How much “local” do you need to know to design a scientifically sound RWE study? I believe there are at least five factors making China’s RWE studies really interesting: 3. Not only the quality, but also the integrity, of RWE studies vary significantly. “Wherever there are flowers, there are weeds too”. Not long ago, real world studies were even used by a few companies as a new way to bribe doctors (e.g., via large investigator grants). The situation is better nowadays. But still, you need to stay awake when designing and conducting your study. You can get whatever result you want from real world data, if not careful and vigilant enough. The 2024 Nature paper below shows how severe the problem can be.

5

1 Comment

Next week, at “Friends of RWE”, the CEO of 1MData, Ms. Min Ma, will e-visit Parexel and introduce her data network in China. At mid-night of a Saturday, 2019, Min (Beijing) called me (Boston) for urgent help. She was competing for a contract to construct a National Cardiovascular Database. We chatted for hours while I was half-sleep. The next day, she asked me to draft some PowerPoint slides. I spent the whole Sunday on it, so she can use on Monday. Guess how much I charged her? Then in 2020, I was asked to create an RWE roadmap of describing drug prescription and utility pattern of a certain cardiovascular disease in China, in 4 days. I called Min. She asked her company“all hands on deck”, worked with me days and nights and produced a slide deck in 3 days. Guess how much she charged me? The answers of both questions are “$0”. It’s bad business model, I know. But Min later won the contract to build the National Cardiovascular Database; we were in a better position to bid for a set of multi-hundred million cardiovascular disease clinical trials. Early engagement is often where idea shines, smart minds clash and trust grows. Did someone ask how to increase “hitting rate”? 😀

5

1 Comment

Check out our recent talk, "The best end-to-end deep-learning practices" at statgen 2024 authored by Jake Gagnon, Hangyu Liu, Lira Pi, and Himanshu Pandya https://lnkd.in/e3_D7Esh #DeepLearning #MachineLearning

11

Spatial transcriptomics not only deepens our comprehension of human health and disease, but also holds promise for drug discovery, particularly where single-cell techniques fall short. At ZS Discovery, we're dedicated to helping clients utilize spatial omics to advance drug discovery. 👉 Read more about how we are at the forefront of this groundbreaking field: https://lnkd.in/dFY-J_NG

33

Tonight, Parexel will have our 50th “Friends of RWE” workshop in APAC. The topic will be, artificial intelligence in clinical R&D. Nowadays, whenever AI is mentioned, we are talking about LLM. But, in the not-long-ago past, preditive model on imaging, omics, digital and clinical data was hot. Tonight, we will cover both. A guest speaker will firstly talk about LLM and its applications in clinical data management in China; I will then introduce the RWE studies I led/involved, e.g., (1) clinicians used AI to help reading CT images by “3D reconstruction”, to reduce the surgery time and cost for early Lung Cancer patients; (2) clinicians used AI for patient management after Lung Cancer surgery, which reduces recovery time meaningfully and significantly; (3) other interesting ideas from real-world clinicians such as how AI may help to identify prenatal risk of baby osteoarthritis; early differentiation between OA and RA; quick and not-so-dirty diagnosis with medical images. Then the“Friends of RWE” series will retire, after four years.

6

Excited to share the latest feature in our "Partnering Spotlight" series, where we share some of the connections we are building to foster scientific innovation in healthcare. In this edition, our very own Neha Kaushal sits down with Daniel Anderson, Professor of Chemical Engineering at MIT, to discuss the potential of innovative #mRNA applications in vaccines and novel treatments for genetic diseases. Check out the video to learn more about our collaboration! https://lnkd.in/eHwpyjeY #vaccines #immunoscience

40

1 Comment

We recently sat down with Dr. George Wang, Vice President of Discovery and Preclinical Services at WuXi Biologics to discuss the importance of looking at developability of an antibody early in the drug discovery process. In the podcast, The Importance of Evaluating Developability in the Antibody Discovery Stage, Dr. Wang defines developability and its significance in achieving scalable production during CMC development, which is essential for large-scale manufacturing before clinical trials. He emphasizes the importance of identifying and addressing developability concerns early in the discovery stage to mitigate risks and ensure cost-effective development. Dr. Wang provides examples where developability studies have helped prevent unforeseen costs and timeline disruptions during biologics discovery and preclinical development phases. He underscores that assessing developability can reveal issues with product aggregation, stability, solubility, or manufacturing efficiencies. https://lnkd.in/g7qY9kXs

2

❔ How do we position regional and community sites for success and mitigate risks for sponsors? ❔ In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. 🚧 That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/dRuWPrWb #ResearchSites #Oncology #NovelInsights

4